查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008495

膠質母細胞瘤多形性治療市場：依治療方法、藥物類別、治療階段和最終用戶分類－2026-2032年全球市場預測

Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line Of Therapy, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，多形性膠質母細胞瘤治療市場價值將達到 36.5 億美元，到 2026 年將成長至 39.7 億美元，到 2032 年將達到 64.1 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 36.5億美元
預計年份：2026年 39.7億美元
預測年份 2032 64.1億美元
複合年成長率 (%) 8.35%

多形性膠質母細胞瘤治療現狀的策略概述：重點關注臨床挑戰、創新動能和相關人員的優先事項

多形性膠質母細胞瘤仍然是神經腫瘤學領域最具挑戰性的臨床難題之一，其特徵是高度侵襲性的生物學特性、分子異質性以及難以維持治療反應。儘管基因組分析、免疫腫瘤學和標靶治療的進展為治療性介入開闢了新的途徑，但臨床路徑仍需要神經外科、放射腫瘤科、內科腫瘤科和支持治療團隊之間的密切合作。因此，參與研究、臨床治療和商業化的相關人員必須權衡短期醫療服務需求與對有望提高生存率和生活品質的創新技術的長期投資。

精準醫學的突破、免疫療法的進步以及多學科綜合合作模式的推動，正在發生變革性的變化，重塑膠質母細胞瘤的治療。

在精準醫療、免疫療法和整合醫療服務的推動下，膠質母細胞瘤的治療模式正在發生重大變化。分子分型和先進的定序技術正促使臨床思維從單一的治療方案轉向以生物標記主導，從而靶向特定的癌基因驅動因子和腫瘤微環境特徵。同時，包括查核點抑制劑和疫苗平台在內的免疫療法正逐步進入後期臨床試驗和聯合治療，促使人們重新評估治療順序和患者選擇標準。

評估美國貿易政策和關稅調整對膠質母細胞瘤治療供應鏈和創新網路的累積影響。

美國貿易政策和關稅政策的變化可能會影響膠質母細胞瘤的治療體系，具體表現在成本結構、關鍵投入品的供應以及跨境合作研究的進展速度等方面。活性成分、生物製藥組分或專用設備的關稅調整可能會增加製造商和醫療系統的採購成本，進而促使籌資策略轉變，例如生產回流和供應商多元化。加上上游因素的影響，例如試劑和醫療設備前置作業時間延長，這些壓力可能會使臨床試驗的物流更加複雜，並延緩跨國研究的啟動和擴展。

細分分析揭示了治療類型、藥物類別、治療線、最終用戶和分銷管道如何共同影響臨床策略和商業化。

精準的細分觀點揭示了治療創新如何與臨床實踐、支付方預期和分銷現實相互交織。按治療類型分類，主要類別包括藥物治療、放射線治療、支持性治療和外科手術。藥物治療涵蓋化療、基因治療、免疫療法和標靶治療等具體療法。化療藥物包括Carmustine、合併化療和Temozolomide等；基因治療又細分為基因編輯和溶瘤病毒療法；免疫治療分為查核點抑制劑和疫苗；標靶治療藥物包括Bevacizumab和EGFR抑制劑等。放射線治療包括近距離放射、體外放射治療和放射外科手術。支持性治療包括抗癲癇藥物和皮質類固醇，外科手術則涵蓋從切片檢查到開顱手術等各種治療方法。

影響美洲、歐洲、中東和非洲以及亞太地區的區域趨勢，這些趨勢影響著醫療服務取得、監管重點和醫療服務模式。

區域差異對膠質母細胞瘤治療方法的研發、核准和應用有著至關重要的影響。在美洲，先進的臨床試驗基礎設施、集中的癌症中心和完善的醫保報銷機制支持新治療方法的快速上市，而支付方的審查和預算考慮仍然是商業化規劃的關鍵因素。歐洲、中東和非洲地區的情況則較為複雜，監管路徑各異，獲得專業神經外科服務的途徑也存在差異，醫療技術評估的時間節點也存在顯著差異，這些都會影響藥物的上市和定價策略。亞太地區的特點是臨床研究能力的快速發展、政府對國內生產的重視以及對精準腫瘤學能力的持續投入，這些因素共同為區域夥伴關係和本地打入市場策略創造了充滿活力的機會。

影響膠質母細胞瘤治療發展的競爭格局，重點在於研發重點、臨床管線差異化、夥伴關係和生產重點。

透過差異化的研發組合、有針對性的合作以及建立嚴謹的生產體系，各公司在膠質母細胞瘤領域的策略正變得日益清晰。主要企業優先進行強力的轉化項目，旨在檢驗生物標記、最佳化聯合治療，並產生支持監管申報和與保險公司溝通的機制證據。臨床研發管線包括後期免疫療法聯合治療、針對可治療突變的分子標靶藥物以及旨在增強藥物向中樞神經系統滲透性的創新遞送技術。為了保持競爭優勢，各公司正在加速推進適應性試驗設計、籃子試驗和適應症拓展，並投資產生真實世界數據（REW），以提供可用於報銷申請的寶貴資訊。

為行業領導者提供可操作的建議，以加速轉化研究、最佳化臨床路徑並增強以患者為中心的醫療服務。

產業領導者應優先考慮一系列切實可行的舉措，以加速轉化研究的進展並改善患者可及性。首先，研發投資應集中在檢驗生物標記和聯合治療策略的高價值轉化路徑，從而提高臨床成功率並促進與監管機構的合作。其次，應採用靈活的試驗設計和可操作的終點指標，兼顧科學嚴謹性和操作可行性，從而提高患者招募效率，並在不同人群中清晰地檢測到訊號。第三，應加強臨床、監管、生產和銷售團隊之間的跨職能協作，以確保研發項目能夠獲得報銷，並從一開始就考慮到供應鏈的實際情況。

本文檔概述了獲取膠質母細胞瘤相關資訊的調查方法，包括一級和二級資料收集、專家諮詢和分析框架。

本分析的調查方法結合了以臨床專家、臨床實驗研究員、製藥公司和患者權益組織為對象的定性研究，以及整契約行評審文獻、臨床試驗註冊數據和監管指南的結構化二手研究。專家訪談提供了關於臨床實踐差異、試驗設計權衡和真實臨床環境中治療路徑的背景信息，而二手信息則用於對治療機制、安全性特徵和治療方法的比較證據進行三角驗證。分析框架包括交叉細分映射、產品線優先矩陣和情境規劃，以評估不同政策和供應鏈背景下的營運和商業影響。

一份總結報告，將臨床現實、政策影響和創新機會聯繫起來，以指導研究、醫療保健和商業的下一步發展。

總之，膠質母細胞瘤治療領域正處於快速科學進展與持續臨床複雜性交彙的階段。分子診斷、免疫療法聯合應用和局部控制技術的進步為改善患者預後提供了切實的機會，但要將這些進步轉化為持續的臨床獲益，需要整合研發、生產和患者獲取等各個環節的策略。政策和供應鏈趨勢，包括貿易因素和區域監管差異，進一步增加了營運的複雜性，必須積極應對，以確保臨床試驗的持續性和患者的治療可及性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 多形性膠質母細胞瘤治療市場：依治療方法

  • 藥物治療
    • 化療
      • Carmustine
      • 合併化療
      • Temozolomide
    • 基因治療
      • 基因編輯
      • 溶瘤病毒療法
    • 免疫療法
      • 查核點抑制劑
      • 疫苗
    • 標靶治療
      • Bevacizumab
      • EGFR抑制劑
  • 放射線治療
    • 近距離放射治療
    • 體外放射治療
    • 放射外科
  • 支持性護理
    • 抗癲癇藥物
    • 皮質類固醇
  • 外科
    • 切片檢查程序
    • 開顱手術

第9章 膠質母細胞瘤多形性治療市場：依藥物類別分類

  • 烷化劑
    • Carmustine
    • Temozolomide
  • 查核點抑制劑
    • Nivolumab
    • Pembrolizumab
  • 單株抗體
  • 溶瘤病毒療法
  • 疫苗療法
    • 樹突細胞疫苗
    • 胜肽疫苗

第10章：膠質母細胞瘤多形性疾病治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第11章 膠質母細胞瘤多形性治療市場：依最終使用者分類

  • 家庭醫療保健
  • 醫院
  • 研究機構
  • 專科診所

第12章 多形性膠質母細胞瘤治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 膠質母細胞瘤多形性治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 膠質母細胞瘤多形性治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國：多形性膠質母細胞瘤治療市場

第16章 中國：多形性膠質母細胞瘤治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AIVITA Biomedical, Inc.
  • Angiochem Inc.
  • Avant Immunotherapeutics, Inc.
  • Bayer AG
  • Chimerix Inc.
  • Daiichi Sankyo Company, Limited
  • Diffusion Pharmaceuticals Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lineage Cell Therapeutics, Inc.
  • Merck & Co. Inc.
  • Moleculin Biotech, Inc.
  • Novocure GmbH
  • OncoSynergy, Inc.
  • Pfizer Inc.
  • Sapience Therapeutics, Inc.
  • SonALAsense
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBI Vaccines Inc.
  • VBL Therapeutics
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market was valued at USD 3.65 billion in 2025 and is projected to grow to USD 3.97 billion in 2026, with a CAGR of 8.35%, reaching USD 6.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 3.97 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 8.35%

Strategic overview of glioblastoma multiforme treatment landscape highlighting clinical challenges, innovation momentum, and stakeholder imperatives

Glioblastoma multiforme remains one of the most formidable clinical challenges in neuro-oncology, defined by aggressive tumor biology, heterogeneity at the molecular level, and entrenched barriers to durable treatment response. Advances in genomic profiling, immuno-oncology, and targeted agents have created new avenues for therapeutic intervention, yet the clinical pathway still requires nuanced coordination among neurosurgery, radiation oncology, medical oncology, and supportive care teams. As a result, stakeholders across research, clinical care, and commercialization must balance near-term care delivery needs with long-term investments in innovation that promise improved survival and quality of life.

This executive summary synthesizes the current therapeutic landscape, highlights pivotal shifts in R&D and commercial strategy, and frames pragmatic actions that leaders can take to align pipelines, partnerships, and patient access programs. By concentrating on translational priorities, operational resilience, and patient-centric delivery models, the document prepares decision-makers to navigate regulatory complexity, supply chain volatility, and evolving reimbursement environments while maintaining focus on clinical outcomes and value creation.

Transformative shifts reshaping glioblastoma care driven by precision medicine breakthroughs, immunotherapy advances, and integrated multidisciplinary models

The glioblastoma treatment landscape is undergoing a period of substantive transformation driven by precision medicine, immunotherapy, and integrated care delivery. Molecular subtyping and advanced sequencing have shifted clinical thinking away from one-size-fits-all approaches toward biomarker-driven interventions that target specific oncogenic drivers or tumor microenvironment characteristics. Concurrently, immunotherapies, including checkpoint inhibitors and vaccine platforms, have moved into late-stage clinical testing and combination strategies, prompting a re-evaluation of therapeutic sequencing and patient selection criteria.

In parallel, improvements in surgical techniques, stereotactic radiosurgery, and radiotherapy planning have strengthened local control approaches and created opportunities for synergistic multimodal regimens. These clinical advances are supported by evolving regulatory frameworks that increasingly recognize the need for adaptive trial designs and real-world evidence to assess benefit in rare and heterogeneous indications. Taken together, these shifts demand that clinical teams, trial designers, and commercial leaders coordinate across disciplines to accelerate translation from bench to bedside while ensuring equitable patient access to emerging therapies.

Assessing the cumulative impact of United States trade policy and tariff adjustments on glioblastoma treatment supply chains and innovation networks

Evolving United States trade policy and tariff considerations can influence the glioblastoma treatment ecosystem by affecting the cost structure, availability of critical inputs, and the operational cadence of cross-border collaborations. Tariff adjustments on active pharmaceutical ingredients, biologics components, or specialized equipment have the potential to raise procurement costs for manufacturers and health systems, which may in turn shift sourcing strategies and prompt reshoring or supplier diversification. When combined with upstream effects such as increased lead times for reagents and devices, these pressures can complicate clinical trial logistics and slow the initiation or expansion of multinational studies.

Beyond pure cost impacts, policy-driven trade dynamics can alter patterns of partnership and licensing. Companies may accelerate in-region manufacturing investments or pursue alternative regulatory routes to mitigate exposure to tariff volatility. This can create both headwinds and opportunities: while near-term disruptions may increase operational complexity, they can also incentivize investments in domestic production capacity, regional supply hubs, and more resilient procurement pathways. For innovation ecosystems, an increased emphasis on supply chain transparency and dual sourcing will be essential, and stakeholders should proactively assess contract terms, inventory strategies, and collaborative manufacturing agreements to preserve continuity for research programs and patient treatment access.

Segmentation analysis revealing how treatment types, drug classes, therapy lines, end users, and distribution channels jointly inform clinical strategy and commercialization

A nuanced segmentation lens reveals where therapeutic innovation intersects with clinical practice, payer expectations, and distribution realities. When examined by treatment type, key categories include Drug Therapy, Radiotherapy, Supportive Care, and Surgical. Within Drug Therapy there are discrete modalities such as Chemotherapy, Gene Therapy, Immunotherapy, and Targeted Therapy; Chemotherapy itself encompasses agents like Carmustine, Combination Chemotherapy, and Temozolomide, while Gene Therapy subdivides into Gene Editing and Oncolytic Virus Therapy. Immunotherapy splits into Checkpoint Inhibitors and Vaccines, and Targeted Therapy includes agents such as Bevacizumab and EGFR Inhibitors. Radiotherapy covers Brachytherapy, External Beam Radiotherapy, and Radiosurgery, Supportive Care addresses Antiepileptic Drugs and Corticosteroids, and Surgical interventions range from Biopsy Procedures to Craniotomy.

Viewed through the prism of drug class, alkylating agents such as Carmustine and Temozolomide remain foundational, while checkpoint inhibitors represented by agents like Nivolumab and Pembrolizumab, monoclonal antibodies exemplified by Bevacizumab, oncolytic virus therapies such as sitimogene ceradenovac, and vaccine platforms including dendritic cell vaccines and peptide vaccines round out the therapeutic palette. Line-of-therapy segmentation differentiates First Line, Second Line, and Third Line approaches, each with distinct clinical endpoints, tolerability priorities, and evidence thresholds. End users span Home Healthcare, Hospitals, Research Institutes, and Specialty Clinics, and distribution channels move through Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Together, these segmentation dimensions provide a structured framework for assessing clinical utility, development risk, and commercial pathways, enabling stakeholders to target investments, design trials, and configure go-to-market strategies that map to real-world care delivery patterns.

Regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape access, regulatory priorities, and care delivery models

Regional variation exerts a decisive influence on how glioblastoma therapies are developed, approved, and delivered. In the Americas, a combination of advanced clinical trial infrastructure, centralized cancer centers, and established reimbursement mechanisms supports rapid adoption of novel therapeutics, though payer scrutiny and budget impact considerations remain influential in commercialization planning. Europe, the Middle East & Africa presents a heterogeneous picture with diverse regulatory pathways, variable access to specialized neurosurgical capabilities, and significant differences in health technology assessment timelines that affect uptake and pricing strategies. In Asia-Pacific, the landscape is characterized by fast-expanding clinical research capacity, strong government interest in domestic manufacturing, and growing investment in precision oncology capabilities that together create dynamic opportunities for regional partnerships and localized market entry strategies.

Regulatory nuance, reimbursement modalities, and healthcare delivery models differ materially across these regions, so manufacturers and health systems must calibrate clinical evidence generation and access programs accordingly. Cross-regional collaborations, technology transfer arrangements, and tailored patient support mechanisms can bridge gaps in care delivery. By aligning clinical development plans with regional regulatory expectations and delivery infrastructures, stakeholders can improve the likelihood of timely patient access while managing operational and commercial risk.

Competitive landscape spotlighting R&D focus, clinical pipeline differentiation, partnerships, and manufacturing priorities shaping glioblastoma therapy development

Company strategies in glioblastoma are increasingly defined by differentiated R&D portfolios, targeted partnerships, and deliberate manufacturing positioning. Leading organizations prioritize robust translational programs to validate biomarkers, optimize combination regimens, and generate mechanistic evidence that supports regulatory submissions and payer dialogue. Clinical pipelines show a mix of late-stage combination immunotherapies, targeted agents addressing actionable mutations, and innovative delivery technologies aimed at improving central nervous system penetration. To sustain competitive advantage, companies are investing in adaptive trial designs, basket studies, and real-world evidence generation that can accelerate label expansions and inform reimbursement dossiers.

Partnerships between biopharma, academic centers, and contract manufacturing organizations have grown more strategic, with many companies seeking co-development arrangements to share clinical risk and access specialized manufacturing for cell and gene therapies. Manufacturing considerations-particularly for complex biologics and viral vectors-drive decisions about geographic capacity, quality systems, and supply chain redundancy. Commercially, companies that integrate early engagement with clinicians, payers, and patient advocacy groups position themselves to streamline uptake, while those that invest in data infrastructure and outcomes measurement are better equipped to demonstrate value across payers and health systems.

Actionable recommendations for industry leaders to accelerate translational research, optimize clinical pathways, and strengthen patient-centric access

Industry leaders should prioritize a set of pragmatic actions that accelerate translational progress and improve patient access. First, align R&D investments to high-value translational pathways that validate biomarkers and combination strategies, thereby improving the probability of clinical success and facilitating regulatory engagement. Second, adopt flexible trial architectures and pragmatic endpoints that balance scientific rigor with operational feasibility, enabling more efficient patient enrollment and clearer signal detection across heterogeneous populations. Third, strengthen cross-functional collaborations among clinical operations, regulatory affairs, manufacturing, and commercial teams to ensure that development programs are informed by reimbursement and supply chain realities from inception.

In parallel, leaders should reinforce patient-centric access strategies by investing in hub-and-spoke care models, digital health tools for monitoring and adherence, and tailored support programs that reduce barriers to therapy initiation and continuation. Risk mitigation measures such as dual sourcing, contingency inventory planning, and contractual protections can preserve continuity for trials and commercial supply. Finally, strategic partnerships with academic centers, specialty clinics, and third-party manufacturers can accelerate capability building while distributing program risk, enabling organizations to respond quickly to clinical opportunities and policy shifts.

Research methodology outlining primary and secondary data collection, expert engagement, and analytical frameworks for glioblastoma insights

The methodology underpinning this analysis combines primary qualitative engagement with expert clinicians, trial investigators, manufacturers, and patient advocates alongside structured secondary research synthesizing peer-reviewed literature, clinical trial registries, and regulatory guidance. Expert interviews provided contextual nuance on clinical practice variation, trial design trade-offs, and real-world treatment pathways, while secondary sources were used to triangulate evidence on therapeutic mechanisms, safety profiles, and comparative modality performance. Analytical frameworks included cross-segmentation mapping, pipeline prioritization matrices, and scenario planning to evaluate operational and commercial implications under differing policy and supply chain conditions.

This approach balances depth and breadth: primary engagement ensures current, practice-based insights and captures emerging clinical sentiment, while systematic secondary synthesis provides a reproducible evidence base. Where appropriate, the analysis incorporates structured sensitivity around procurement and regulatory scenarios to highlight resilience levers and strategic contingencies that stakeholders can deploy in response to evolving external conditions.

Concluding synthesis that connects clinical realities, policy influences, and innovation opportunities to guide research, care, and commercial next steps

In conclusion, the glioblastoma treatment arena sits at the intersection of rapid scientific progress and persistent clinical complexity. Molecular diagnostics, immunotherapy combinations, and advances in local control techniques offer tangible opportunities to improve patient outcomes, yet translating these advances into consistent clinical benefit requires integrated strategy across development, manufacturing, and access functions. Policy and supply chain dynamics, including trade considerations and regional regulatory variability, add layers of operational complexity that must be proactively managed to protect trial continuity and patient access.

Moving forward, stakeholders who synchronize translational priorities with pragmatic operational plans will be best positioned to convert innovation into meaningful therapeutic options. Cross-sector collaboration, investments in resilient supply chains, and sustained dialogue with payers and regulatory authorities will accelerate adoption of high-value therapies while maintaining the focus on patient-centered outcomes and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glioblastoma Multiforme Treatment Market, by Treatment Type

  • 8.1. Drug Therapy
    • 8.1.1. Chemotherapy
      • 8.1.1.1. Carmustine
      • 8.1.1.2. Combination Chemotherapy
      • 8.1.1.3. Temozolomide
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Gene Editing
      • 8.1.2.2. Oncolytic Virus Therapy
    • 8.1.3. Immunotherapy
      • 8.1.3.1. Checkpoint Inhibitors
      • 8.1.3.2. Vaccines
    • 8.1.4. Targeted Therapy
      • 8.1.4.1. Bevacizumab
      • 8.1.4.2. EGFR Inhibitors
  • 8.2. Radiotherapy
    • 8.2.1. Brachytherapy
    • 8.2.2. External Beam Radiotherapy
    • 8.2.3. Radiosurgery
  • 8.3. Supportive Care
    • 8.3.1. Antiepileptic Drugs
    • 8.3.2. Corticosteroids
  • 8.4. Surgical
    • 8.4.1. Biopsy Procedures
    • 8.4.2. Craniotomy

9. Glioblastoma Multiforme Treatment Market, by Drug Class

  • 9.1. Alkylating Agents
    • 9.1.1. Carmustine
    • 9.1.2. Temozolomide
  • 9.2. Checkpoint Inhibitors
    • 9.2.1. Nivolumab
    • 9.2.2. Pembrolizumab
  • 9.3. Monoclonal Antibodies
  • 9.4. Oncolytic Virus Therapies
  • 9.5. Vaccine Therapies
    • 9.5.1. Dendritic Cell Vaccines
    • 9.5.2. Peptide Vaccines

10. Glioblastoma Multiforme Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Glioblastoma Multiforme Treatment Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Glioblastoma Multiforme Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Glioblastoma Multiforme Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Glioblastoma Multiforme Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Glioblastoma Multiforme Treatment Market

16. China Glioblastoma Multiforme Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AIVITA Biomedical, Inc.
  • 17.6. Angiochem Inc.
  • 17.7. Avant Immunotherapeutics, Inc.
  • 17.8. Bayer AG
  • 17.9. Chimerix Inc.
  • 17.10. Daiichi Sankyo Company, Limited
  • 17.11. Diffusion Pharmaceuticals Inc.
  • 17.12. DNAtrix, Inc.
  • 17.13. Eisai Co., Ltd.
  • 17.14. F. Hoffmann-La Roche Ltd
  • 17.15. Karyopharm Therapeutics Inc.
  • 17.16. Kazia Therapeutics Limited
  • 17.17. Lineage Cell Therapeutics, Inc.
  • 17.18. Merck & Co. Inc.
  • 17.19. Moleculin Biotech, Inc.
  • 17.20. Novocure GmbH
  • 17.21. OncoSynergy, Inc.
  • 17.22. Pfizer Inc.
  • 17.23. Sapience Therapeutics, Inc.
  • 17.24. SonALAsense
  • 17.25. Sumitomo Dainippon Pharma Oncology, Inc.
  • 17.26. Sun Pharmaceutical Industries Ltd.
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. VBI Vaccines Inc.
  • 17.29. VBL Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)

TABL